

Sample Counts by Tumour Type and Therapy Class

NBL	16	61	2	58		18	16	72	68	66	3		58	29	22
HGG	5	2	3			8	1	7	8	4	1		11	14	2
OST		31	30					14	31	12	2	2	1	4	2
BALL		20	21	4			1	16		13	5		21	4	7
EWS		17	1	8	6	5		19		15			19	9	
ERMS		11		12	14	1		16	2	5	3		15	9	
DMG									1				1	1	
ARMS		6		10	10	1	2	13		9	3		11	7	
WT		15		4	15			9	8	9			15	9	
EPD	2		4	1			1	7	7	5	1		6	8	
AML		8	8		1			1		8					2
US		5		3	1	1		6	2	6			5	2	
MBL	1		5					7	8	2	1		8	8	3
MRT		5			4			5	4	5	3		5	1	
ATRT		3			3	3		3	3				3	3	
SS		4						4		1				2	
DSRCT		5		4		2		5	2	5			5	2	1
MPNST		3						3						2	
ACC		5							5	5					5
HCC		2							2		1				
HB		5		3				4	5	4			4		1
LGG									1				1		
MFT					3			3		2			3	1	
MPN		3	3				3	3		3			3		3
ES		1						1						2	
PTC	1		1			1							1		
MN														2	
EMBCNS			2					2	2				2	2	2
CD														2	
CPC				1	1	1		1	1	1			1	1	
Other	2	12	12	4	1	5	2	19	13	14	5	3	18	14	6
Total	27	224	92	112	58	46	26	240	173	194	28	5	217	138	56
	Alkylating agent, Other	Anthracyclines	Antimetabolite	Camptothecin analogs	Chromomycins	Hydrazines and Triazines	Monoclonal antibody	Mustard gas derivative	Platinums	Podophyllotoxins	Targeted therapy	Taxanes	Vinca alkaloids	Radiation	Other

Therapy Class